Halozyme Therapeutics Return On Tangible Equity 2010-2025 | HALO

Halozyme Therapeutics return on tangible equity for the quarter ending March 31, 2025 was -112.59.

  • Halozyme Therapeutics average return on tangible equity for 2024 was -60.42, a 107.77% increase from 2023.
  • Halozyme Therapeutics average return on tangible equity for 2023 was -29.08, a 87.28% increase from 2022.
  • Halozyme Therapeutics average return on tangible equity for 2022 was -228.62, a 205.46% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Halozyme Therapeutics Return On Tangible Equity 2010-2025 | HALO

  • Halozyme Therapeutics average return on tangible equity for 2024 was -60.42, a 107.77% increase from 2023.
  • Halozyme Therapeutics average return on tangible equity for 2023 was -29.08, a 87.28% increase from 2022.
  • Halozyme Therapeutics average return on tangible equity for 2022 was -228.62, a 205.46% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.